Cargando…
A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up
RATIONALE: As suggested by the 2012 KDIGO guidelines, persistent elevation of serum creatinine > 3.5 mg/dl (> 309 μmol/l) (or an estimated glomerular filtration rate < 30 ml/min per 1.73 m(2) is one of contradictions for the use of immunosuppressive therapy in membranous nephropathy. PATIEN...
Autores principales: | Zhou, Xu-Jie, Zhou, Fu-De, Wang, Su-Xia, Zhao, Ming-Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024028/ https://www.ncbi.nlm.nih.gov/pubmed/29924035 http://dx.doi.org/10.1097/MD.0000000000011184 |
Ejemplares similares
-
Remission of Refractory Membranous Nephropathy by Low-dose Rituximab: A Case Report
por: Wang, Xiao-Pei, et al.
Publicado: (2016) -
Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021) -
Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2022) -
Rituximab in patients with membranous nephropathy and kidney insufficiency
por: Guo, Yanhong, et al.
Publicado: (2022) -
Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience
por: Katsuno, Takayuki, et al.
Publicado: (2017)